Literature DB >> 26375403

C-Mpl Is Expressed on Osteoblasts and Osteoclasts and Is Important in Regulating Skeletal Homeostasis.

Tomas E Meijome1, Jenna T B Ekwealor1, R Adam Hooker1, Ying-Hua Cheng1, Wendy A Ciovacco1,2, Sanjeev M Balamohan1, Trishya L Srinivasan1, Brahmananda R Chitteti3, Pierre P Eleniste4, Mark C Horowitz2, Edward F Srour3, Angela Bruzzaniti4, Robyn K Fuchs5, Melissa A Kacena1,2.   

Abstract

C-Mpl is the receptor for thrombopoietin (TPO), the main megakaryocyte (MK) growth factor, and c-Mpl is believed to be expressed on cells of the hematopoietic lineage. As MKs have been shown to enhance bone formation, it may be expected that mice in which c-Mpl was globally knocked out (c-Mpl(-/-) mice) would have decreased bone mass because they have fewer MKs. Instead, c-Mpl(-/-) mice have a higher bone mass than WT controls. Using c-Mpl(-/-) mice we investigated the basis for this discrepancy and discovered that c-Mpl is expressed on both osteoblasts (OBs) and osteoclasts (OCs), an unexpected finding that prompted us to examine further how c-Mpl regulates bone. Static and dynamic bone histomorphometry parameters suggest that c-Mpl deficiency results in a net gain in bone volume with increases in OBs and OCs. In vitro, a higher percentage of c-Mpl(-/-) OBs were in active phases of the cell cycle, leading to an increased number of OBs. No difference in OB differentiation was observed in vitro as examined by real-time PCR and functional assays. In co-culture systems, which allow for the interaction between OBs and OC progenitors, c-Mpl(-/-) OBs enhanced osteoclastogenesis. Two of the major signaling pathways by which OBs regulate osteoclastogenesis, MCSF/OPG/RANKL and EphrinB2-EphB2/B4, were unaffected in c-Mpl(-/-) OBs. These data provide new findings for the role of MKs and c-Mpl expression in bone and may provide insight into the homeostatic regulation of bone mass as well as bone loss diseases such as osteoporosis.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  BONE MASS; C-Mpl; OSTEOBLASTS; OSTEOCLASTS; THROMBOPOIETIN

Mesh:

Substances:

Year:  2015        PMID: 26375403      PMCID: PMC4883670          DOI: 10.1002/jcb.25380

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  38 in total

1.  A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation.

Authors:  X Q Yan; D Lacey; D Hill; Y Chen; F Fletcher; R G Hawley; I K McNiece
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

2.  Expression and regulation of Ly-6 differentiation antigens by murine osteoblasts.

Authors:  M C Horowitz; A Fields; D DeMeo; H Y Qian; A L Bothwell; E Trepman
Journal:  Endocrinology       Date:  1994-09       Impact factor: 4.736

3.  Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.

Authors:  F J de Sauvage; P E Hass; S D Spencer; B E Malloy; A L Gurney; S A Spencer; W C Darbonne; W J Henzel; S C Wong; W J Kuang
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

4.  Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis.

Authors:  N Methia; F Louache; W Vainchenker; F Wendling
Journal:  Blood       Date:  1993-09-01       Impact factor: 22.113

5.  Structure and transcription of the human c-mpl gene (MPL).

Authors:  V Mignotte; I Vigon; E Boucher de Crèvecoeur; P H Roméo; V Lemarchandel; S Chrétien
Journal:  Genomics       Date:  1994-03-01       Impact factor: 5.736

6.  Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP).

Authors:  C M Stanford; P A Jacobson; E D Eanes; L A Lembke; R J Midura
Journal:  J Biol Chem       Date:  1995-04-21       Impact factor: 5.157

7.  Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro.

Authors:  V C Broudy; N L Lin; K Kaushansky
Journal:  Blood       Date:  1995-04-01       Impact factor: 22.113

8.  Thrombocytopenia in c-mpl-deficient mice.

Authors:  A L Gurney; K Carver-Moore; F J de Sauvage; M W Moore
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

9.  Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development.

Authors:  R A Shivdasani; M F Rosenblatt; D Zucker-Franklin; C W Jackson; P Hunt; C J Saris; S H Orkin
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

10.  Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.

Authors:  F J de Sauvage; K Carver-Moore; S M Luoh; A Ryan; M Dowd; D L Eaton; M W Moore
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

View more
  7 in total

1.  Lnk Deficiency Leads to TPO-Mediated Osteoclastogenesis and Increased Bone Mass Phenotype.

Authors:  David J Olivos; Marta Alvarez; Ying-Hua Cheng; Richard Adam Hooker; Wendy A Ciovacco; Monique Bethel; Haley McGough; Christopher Yim; Brahmananda R Chitteti; Pierre P Eleniste; Mark C Horowitz; Edward F Srour; Angela Bruzzaniti; Robyn K Fuchs; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2017-04-18       Impact factor: 4.429

2.  Megakaryocyte and Osteoblast Interactions Modulate Bone Mass and Hematopoiesis.

Authors:  Marta B Alvarez; LinLin Xu; Paul J Childress; Kevin A Maupin; Safa F Mohamad; Brahmananda R Chitteti; Evan Himes; David J Olivos; Ying-Hua Cheng; Simon J Conway; Edward F Srour; Melissa A Kacena
Journal:  Stem Cells Dev       Date:  2018-05-15       Impact factor: 3.272

3.  The effects of bone morphogenetic protein 2 and thrombopoietin treatment on angiogenic properties of endothelial cells derived from the lung and bone marrow of young and aged, male and female mice.

Authors:  Ushashi C Dadwal; Fazal Ur Rehman Bhatti; Olatundun D Awosanya; Rohit U Nagaraj; Anthony J Perugini; Seungyup Sun; Conner R Valuch; Caio de Andrade Staut; Stephen K Mendenhall; Nikhil P Tewari; Sarah L Mostardo; Murad K Nazzal; Hanisha L Battina; Donghui Zhou; Deepa Kanagasabapathy; Rachel J Blosser; Patrick L Mulcrone; Jiliang Li; Melissa A Kacena
Journal:  FASEB J       Date:  2021-09       Impact factor: 5.834

4.  Megakaryocytes promote bone formation through coupling osteogenesis with angiogenesis by secreting TGF-β1.

Authors:  Yong Tang; Mengjia Hu; Yang Xu; Fang Chen; Shilei Chen; Mo Chen; Yan Qi; Mingqiang Shen; Cheng Wang; Yukai Lu; Zihao Zhang; Hao Zeng; Yong Quan; Fengchao Wang; Yongping Su; Dongfeng Zeng; Song Wang; Junping Wang
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

5.  Megakaryocytes promote osteoclastogenesis in aging.

Authors:  Deepa Kanagasabapathy; Rachel J Blosser; Kevin A Maupin; Jung Min Hong; Marta Alvarez; Joydeep Ghosh; Safa F Mohamad; Alexandra Aguilar-Perez; Edward F Srour; Melissa A Kacena; Angela Bruzzaniti
Journal:  Aging (Albany NY)       Date:  2020-07-07       Impact factor: 5.682

Review 6.  Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy.

Authors:  Arbi Aghali
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

Review 7.  From the Clinical Problem to the Basic Research-Co-Culture Models of Osteoblasts and Osteoclasts.

Authors:  Sheng Zhu; Sabrina Ehnert; Marc Rouß; Victor Häussling; Romina H Aspera-Werz; Tao Chen; Andreas K Nussler
Journal:  Int J Mol Sci       Date:  2018-08-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.